Charles G. Drake - Concepedia

Author

Charles G. Drake

Also Known As

A Rahman, Angelo Demarzo, C Drake, C G DRAKE, C G Drake, C. Drake, C. G. DRAKE, C. G. Drake, C.G. Drake, CHARLES G. DRAKE

1.2K

Publications

89.8K

Citations

133

H-Index

264

Concepts

All Affiliations

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine Columbia University Irving Medical Center Dana-Farber Cancer Institute

About

Charles G. Drake is an author at Johns Hopkins University specializing in medicine, immunology, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	75	190	27.4K
2	Health Sciences	19	26	3K
3	Public Health	5	5	393
4	Engineering	1	1	19
5	Natural Sciences	1	1	2.3K

Charles G. Drake

346

Publications

71.3K

Citations

119

H-Index

Page 1

	Year	Citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, New England Journal of Medicine	2012	12.5K
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, New England Journal of Medicine	2012	7.9K
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Julie R. Brahmer, Charles G. Drake, Ira Wollner, Journal of Clinical Oncology	2010	2.9K
A draft map of the human proteome Min‐Sik Kim, Sneha M. Pinto, Derese Getnet, Nature BiologyProteomic TechnologyNatural SciencesMedicineProteasome	2014	2.3K
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape Seng‐Ryong Woo, Meghan E. Turnis, Monica V. Goldberg, Cancer Research T-regulatory CellImmunologyImmune RegulationImmunoeditingImmunotherapy	2011	1.6K
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Eugene D. Kwon, Charles G. Drake, H. I. Scher, The Lancet Oncology UrologyOncologyDocetaxel ChemotherapyClinical TrialsImmune Checkpoint Inhibitor	2014	1.5K
Role of LAG-3 in Regulatory T Cells Ching-Tai Huang, Creg J. Workman, Dallas B. Flies, Immunity Signal TransductionT-regulatory CellImmunologyRegulatory T CellsAutoimmunity	2004	1.3K
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma Diana Miao, Claire A. Margolis, Wenhua Gao, Science	2018	1.3K
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas Jing Zeng, Alfred P. See, Jillian Phallen, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyAnti-pd-1 BlockadeRadiation TherapyGliomaMedicine	2013	889
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma Sofía Lyford-Pike, Shiwen Peng, Geoffrey D. Young, Cancer Research Hpv-associated HeadImmunologyImmune RegulationPathologyImmunoediting	2013	759

Page 1